Midodrine: a novel therapeutic for refractory chylothorax.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 24008957.
- Also identified by DOI 10.1378/chest.12-3081.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thoracic duct injury is a rare but serious complication following surgery of the neck or chest that leads to uncontrolled chyle leak. Conventional management includes drainage, nutritional modification, or aggressive surgical interventions such as thoracic duct ligation, flap coverage, fibrin glue, or talc pleurodesis; few successful medical therapeutics are available. We report a case of a high-output chylothorax refractory to aggressive medical and surgical interventions. Chyle output decreased substantially after initiating midodrine, an α1-adrenergic agonist that causes vasoconstriction of the lymph system, reducing chyle flow. This case report suggests that midodrine may be a novel therapeutic for refractory chyle leaks.
Medical subject headings
- Chylothorax
- Midodrine
- Thoracic Duct
- Vasoconstrictor Agents